10-May-2024
Novo Nordisk, Flagship to develop next-generation obesity drugs
Seeking Alpha News (Thu, 9-May 1:22 PM ET)
Oppenheimer Sticks to Their Buy Rating for Seres Therapeutics (MCRB)
TipRanks (Thu, 9-May 7:56 AM ET)
PRNewswire (Thu, 9-May 7:00 AM ET)
Buy Rating Affirmed for Seres Therapeutics Amidst Strong Sales Trajectory and Promising Pipeline
TipRanks (Thu, 9-May 6:59 AM ET)
Seres Therapeutics at Risk of Nasdaq Delisting: A Race Against Time to Bolster Stock Value
TipRanks (Thu, 9-May 2:01 AM ET)
Benzinga (Wed, 8-May 1:38 PM ET)
ISUN, DTCK and MXCT among mid-day movers
Seeking Alpha News (Wed, 8-May 12:52 PM ET)
Nasdaq Down Over 50 Points; Uber Posts Q1 Loss
Benzinga (Wed, 8-May 10:02 AM ET)
Tivic Health Systems, NewGenIvf Group, Elanco Animal Health among healthcare movers
Seeking Alpha News (Wed, 8-May 10:00 AM ET)
SYTA, IAS and AIRE among pre-market losers
Seeking Alpha News (Wed, 8-May 8:36 AM ET)
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Seres Therapeutics trades on the NASDAQ stock market under the symbol MCRB.
As of May 10, 2024, MCRB stock price declined to $1.02 with 3,581,064 million shares trading.
MCRB has a beta of 1.46, meaning it tends to be more sensitive to market movements. MCRB has a correlation of 0.03 to the broad based SPY ETF.
MCRB has a market cap of $154.03 million. This is considered a Micro Cap stock.
Last quarter Seres Therapeutics reported $0 in Revenue and -$.27 earnings per share. This fell short of revenue expectation by $-250,000 and exceeded earnings estimates by $.07.
In the last 3 years, MCRB stock traded as high as $25.06 and as low as $.54.
The top ETF exchange traded funds that MCRB belongs to (by Net Assets): IWM, VTI, VXF, IWO, SCHA.
MCRB has underperformed the market in the last year with a return of -80.8%, while the SPY ETF gained +27.8%. In the last 3 month period, MCRB fell short of the market, returning -8.9%, while SPY returned +4.2%. However, in the most recent 2 weeks MCRB has outperformed the stock market by returning +23.6%, while SPY returned +2.5%.
MCRB support price is $.94 and resistance is $1.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MCRB stock will trade within this expected range on the day.